Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Alison Laws,Melissa E. Hughes,Jiani Hu,William T. Barry,Laura S. Dominici,Faina Nakhlis,Thanh U. Barbie,Margaret M. Duggan,Anna Weiss,Esther Rhei,Katharine Carter,Suniti Nimbkar,Stuart J. Schnitt,Tari A. King

Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

2019

Alison Laws
Melissa E. Hughes
Jiani Hu
William T. Barry
Laura S. Dominici
Faina Nakhlis
Thanh U. Barbie
Margaret M. Duggan
Anna Weiss
Esther Rhei
Katharine Carter
Suniti Nimbkar
Stuart J. Schnitt
Tari A. King

Background Recent trials have demonstrated the feasibility of sentinel lymph node biopsy (SLNB) for cN1 breast cancer patients after neoadjuvant chemotherapy (NAC). This study evaluated the technical outcomes of SLNB by residual nodal disease volume.

Keywords:

General surgery
NODAL
Radiology
Sentinel lymph node
Breast cancer
Biopsy
Disease
Medicine
Disease burden
Chemotherapy
Population
Surgical oncology
nodal disease
Axillary Lymph Node Dissection

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations